Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A Castro-Gomez
Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: The Combination of Idelalisib and Rituximab
Postdoc journal
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Five Years of Experience With Rituximab Plus High-Dose Dexamethasone for Relapsed/Refractory Chronic Lymphocytic Leukemia
Archives of Medical Science
Medicine
Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Comparative Efficacy of Chronic Lymphocytic Leukemia Treatment With or Without Rituximab
Oncogematologiya
Oncology
Hematology
Rituximab in Combination With High-Dose Methylprednisolone for the Treatment of Chronic Lymphocytic Leukemia
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
